Click on the subcategory below to find drug monographs for that particular area.
Daiichi Sankyo Company announced results from a prespecified subgroup analysis of 771 cancer patients enrolled in its Phase 3 Hokusai-VTW study evaluating the use of edoxaban.
Interim results announced from Gilead's Phase 2 study evaluating GS-9973 for the treatment of patients with relapsed or refractory hematologic malignancies.
Across racial/ethnic groups, diabetes is associated with an increased risk of hepatocellular carcinoma (HCC), with the highest risk seen for Latinos.
Genomic and epigenomic alterations in the PAX gene family are associated with racial disparity in head and neck squamous cell carcinoma (HNSCC) survival.
Results have been announced from Study 101-09, Gilead's Phase 2 study evaluating idelalisib for the treatment of patients with indolent non-Hodgkin's lymphoma (iNHL) that is refractory (non-responsive) to rituximab and to alkylating-agent-containing chemotherapy.
Make prescribing decisions with our comparative charts and treatment algorithms.
Quickly and accurately perform clinical calculations.
Download or print easy-to-read disease leaflets for your patients.
From the January/February 2013 issue of Oncology Nurse Advisor: Nurses need to know how to assess a patient’s ...0.75 CE for Nurses
From the November/December 2012 issue of Oncology Nurse Advisor: The integration of billing procedures into medical records introduces ...0.75 CE for Nurses
Given the decision-making intricacies associated with radical surgery for invasive bladder cancer, there is a real need for ...1.00 AMA PRA Category 1 Credit(s)TM